HOME    | Hepatitis B     | Hepatitis C  
<--- Return to the 56th AASLD Main Page
HIVandHepatitis.com Coverage of Highlights from the
56th Annual Meeting of the American
Association for the Study of Liver Diseases
 November 11 - 15, 2005 San Francisco, California


HBeAg-negative/ HBeAg-positive

First Line Combination Therapy for Chronic Hepatitis B in HBV-HIV Coinfected Patients with Tenofovir Plus Lamivudine versus Sequential Treatment with Tenofovir Monotherapy after Lamivudine Failure - 11/21/05

Histologic Improvement in Patients with Chronic Hepatitis B after Treatment with Peginterferon alfa-2a (Pegasys) Monotherapy - 11/18/05

Maximal Early HBV Suppression is Predictive of Optimal Virologic and Clinical Efficacy in Nucleoside-Treated Hepatitis B Patients: The GLOBE Study - 11/18/05

Five-year Treatment with Adefovir Results in Regression of Liver Fibrosis in Patients with HBeAg-negative Chronic Hepatitis B - 11/16/05

Long-term Treatment with Adefovir Dipivoxil Is More Cost Effective Than Lamivudine for HBeAg-negative Patients with Chronic Hepatitis B - 11/16/05

<--- Return to the 56th AASLD Main Page